Asklepios BioPharmaceutical, Inc. (AskBio)
70 articles with Asklepios BioPharmaceutical, Inc. (AskBio)
-
AskBio to Present Phase 1b Results Investigating AB-1005 (formerly AAV2-GDNF) as Treatment for Parkinson's Disease at AD/PDTM 2023 International Conference on Alzheimer's and Parkinson's Diseases
3/29/2023
Asklepios BioPharmaceutical, Inc. (AskBio) will present the preliminary results of a clinical Phase 1b study investigating the safety and efficacy of AB-1005, an adeno-associated virus 2 (AAV2) glial cell line-derived neurotrophic factor (GDNF) gene therapy for the treatment of mild to moderate Parkinson's disease at the AD/PD™ 2023 Advances in Science & Therapy Conference taking place March 28–April 1, 2023.
-
AskBio Announces Gustavo Pesquin as New CEO
3/9/2023
Asklepios BioPharmaceutical, Inc., a wholly owned and independently operated subsidiary of Bayer AG, announced that Gustavo Pesquin will become the company's next Chief Executive Officer as of March 11, 2023.
-
AskBio Receives European Commission Orphan Drug Designation through its EU-Based subsidiary BrainVectis for AB-1003, a Novel Investigational AAV Gene Therapy for the Treatment of Limb-Girdle Muscular Dystrophy (LGMD)
2/27/2023
Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, announced today that the European Commission (EC) has granted orphan drug designation for AB-1003 (also known as LION-101)* for the treatment of limb-girdle muscular dystrophy (LGMD).
-
Viralgen receives cGMP certification to produce rAAV commercial grade product at new facility in San Sebastian, Spain
1/9/2023
Viralgen Vector Core, an independently operated subsidiary of Asklepios BioPharmaceutical, Inc., and a member of the Bayer worldwide group of companies, has received Certified Good Manufacturing Practices certification for the manufacture of human medicinal products, investigational medicinal products and sterile or biological active substances.
-
ReCode Therapeutics Announces Strategic Collaboration with AskBio to Explore Single Vector Gene-Editing Platform
1/9/2023
ReCode Therapeutics announced today it has signed a multi-year research collaboration and option agreement with Asklepios BioPharmaceutical, Inc. (AskBio).
-
AskBio Announces Strategic Collaboration with ReCode Therapeutics to Explore Single Vector Gene Editing Platform
1/9/2023
Asklepios BioPharmaceutical, Inc. announced today that it has signed a multi-year research collaboration and option agreement with ReCode Therapeutics.
-
Viralgen GMP certification rAAV commercial product
1/9/2023
Viralgen Vector Core, an independently operated subsidiary of Asklepios BioPharmaceutical, Inc., and a member of the Bayer worldwide group of companies, has received Certified Good Manufacturing Practices certification for the manufacture of human medicinal products, investigational medicinal products and sterile or biological active substances.
-
Recombinant Adeno-Associated Virus (rAAV) Technology Pioneered by AskBio's Dr. Jude Samulski is Key Component of All FDA Approved AAV Gene Therapeutics
12/20/2022
Asklepios BioPharmaceutical, Inc. (AskBio) today announced that the FDA's approval of a new adeno-associated virus (AAV) gene therapy to treat adults with hemophilia B marks another milestone for the advancement of AAV therapeutics and highlights the important research contributions made by AskBio Co-Founder, President and Chief Scientific Officer, R. Jude Samulski, PhD.
-
AskBio Co-Founder Jude Samulski Receives Inaugural European Society of Gene and Cell Therapy Founders Award
10/28/2022
Asklepios BioPharmaceutical, Inc. announced that R. Jude Samulski, Ph.D., AskBio President, Co-Founder and Chief Scientific Officer, received the inaugural European Society of Gene and Cell Therapy Founders Award in Edinburgh, Scotland, during the recent ESGCT 29th Congress.
-
BrainVectis will begin assessing a gene therapy for Huntington’s disease in France after receiving clearance from health authorities there to conduct a Phase I/II study.
-
BrainVectis, a subsidiary of AskBio, receives clearance to conduct Phase I/II clinical trial in France for its novel gene therapy for early-stage Huntington's Disease
8/23/2022
Asklepios BioPharmaceutical, Inc., a wholly owned and independently operated subsidiary of Bayer AG, has received clearance to conduct a Phase I/II trial for its novel Huntington's Disease gene therapy, BV-101, in France through its subsidiary BrainVectis.
-
AskBio Bolsters its Global Leadership Team with Two New Executives
8/11/2022
Asklepios BioPharmaceutical , Inc. is adding two industry veterans to advance clinical operations and lead corporate communications.
-
AskBio President of Therapeutics Dr. Katherine High receives Award from American Society of Gene and Cell Therapy
5/23/2022
Asklepios BioPharmaceutical, Inc., a wholly owned and independently operated subsidiary of Bayer AG, announced that Dr. Katherine High, President of Therapeutics, received the Jerry Mendell award for Translational Science from the American Society of Gene and Cell Therapy.
-
AskBio to Present 11 Abstracts at Upcoming American Society of Gene and Cell Therapy's 25th Annual Meeting
5/16/2022
Asklepios BioPharmaceutical, Inc. announced that the Company will present 11 abstracts at the upcoming American Society of Gene & Cell Therapy 25th Annual Meeting being held May 16 – 19, 2022 at the Walter E. Washington Convention Center in Washington, D.C.
-
AskBio and Touchlight Restructure Joint Venture
2/8/2022
Asklepios BioPharmaceutical, Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, and Touchlight, a biotechnology company pioneering enzymatic DNA production, have announced a revised structure to their former joint venture, Touchlight AAV.
-
Bayer has transformed its pipeline by acquiring multiple cell and gene therapy companies, paving the way for life-saving and life-altering therapies for patients with different disease types.
-
AskBio Names Philip Dana Chief Human Resources Officer
1/10/2022
Asklepios BioPharmaceutical, Inc., a leading, clinical-stage adeno-associated virus gene therapy company and a wholly owned and independently operated subsidiary of Bayer AG, announced that Philip Dana has been appointed to its executive team as Chief Human Resources Officer.
-
Hansa Biopharma enters into agreement with AskBio to evaluate feasibility of imlifidase as pre-treatment ahead of gene therapy in Pompe disease
1/3/2022
Hansa Biopharma AB, "Hansa", (Nasdaq Stockholm: HNSA), today announced that it has entered into an agreement with Asklepios BioPharmaceutical, Inc. ("AskBio"), a fully integrated AAV gene therapy company and a fully owned subsidiary of Bayer AG dedicated to developing medicines that improve the quality of life for patients with genetic diseases.
-
AskBio Receives FDA Fast Track Designation for LION-101, a Novel Investigational AAV Gene Therapy for the Treatment of Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
6/28/2021
Asklepios BioPharmaceutical , Inc. announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track Designation for the LION-101 gene therapy program.
-
The U.S. FDA granted Fast Track Designation to three biopharma companies for the treatment of LGMD, episodic bleeding and leukemia.